Zacks.com users have recently been watching Enterprise Products (EPD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Enterprise Products Partners is in an excellent position to capitalize on growing gas demand.
The MLP continues to find new ways to expand.
Enterprise Products Partners L.P. Common Units (NYSE:EPD ) Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ET Company Participants Libby Strait - Senior Director, IR Jim Teague - Co-CEO Randy Fowler - Co-CEO Tug Hanley - SVP, Hydrocarbon Marketing Graham Bacon - EVP and COO Justin Kleiderer - SVP, Pipelines and Terminals Anthony Chovanec - EVP, Fundamentals and Commodity Risk Assessment Natalie Gayden - SVP, Natural Gas Assets Brent Secrest - EVP and CCO Robert Sanders - EVP, Asset Optimization Christopher D'Anna - SVP, Petrochemicals James Bany - SVP, Crude Oil Pipelines and Terminals Conference Call Participants Theresa Chen - Barclays Jean Ann Salisbury - BofA Securities, Inc. Spiro Dounis - Citi Jeremy Tonet - JPMorgan Michael Blum - Wells Fargo Neal Dingmann - Truist Keith Stanley - Wolfe Research John McKay - Goldman Sachs AJ O'Donnell - TPH&Co. Manav Gupta - UBS Operator Thank you for standing by and welcome to Enterprise Products Partners L.P.
Enterprise Products Partners is leveraging its midstream expertise to capitalize on the new market opportunity in carbon dioxide sequestration.
Bill Gross believes MLPs are really attractive right now.
In the closing of the recent trading day, Enterprise Products Partners (EPD) stood at $29.03, denoting a +0.21% change from the preceding trading day.
24/7 Wall St. Insights High-yield dividend stocks are in big demand as interest rates drop.
Enterprise Products Partners (EPD) closed at $29.13 in the latest trading session, marking a -0.21% move from the prior day.
Enterprise Products Partners is one of the highest-quality, high-yielding dividend stocks.
Zacks.com users have recently been watching Enterprise Products (EPD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna rechargeable spinal cord stimulation device.